Highlights Promise of DNAbilize® Platform to Produce New Drug Candidates and Potential Licensing Opportunities HOUSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced highlights from the recent clinical development and operational update conference call and webcast held May 26, 2025. An ar ...